- Overview
- Bayer Group
- Stock
- Debt
- Reports
- Annual Stockholders’ Meeting 2019
- Events
- Inside Information
- News
- Investor News
- Press
- Archive
- Overview
- Investor News 2018
- Investor News 2017
- Investor News 2016
- Investor News 2015
- Investor News 2014
- Investor News 2013
- Investor News 2012
- Investor News 2011
- Investor News 2010
- Investor News 2009
- Investor News 2008
- Investor News 2007
- Investor News 2006
- Investor News 2005
- Investor News 2004
- Investor News 2003
- Investor News 2002
- Investor News 2001
- Investor News 2000
- Handouts
- Downloads
- Service
Investor News
February 15, 2019
Not intended for U.S. and UK Media
Bayer exercised option to obtain full licensing rights for larotrectinib and BAY 2731954 (LOXO-195)
moreFebruary 14, 2019
Not intended for U.S. and UK Media - American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) 2019
Bayer's darolutamide plus androgen deprivation therapy (ADT) significantly extends metastasis-free survival with a favorable safety profile compared to placebo plus ADT in non-metastatic castration-resistant prostate cancer
moreJanuary 08, 2019
New predictive seed placement technology delivers strong results in 2018: